455 related articles for article (PubMed ID: 11709336)
1. Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication.
Takashima K; Miyake H; Furuta RA; Fujisawa JI; Iizawa Y; Kanzaki N; Shiraishi M; Okonogi K; Baba M
Antimicrob Agents Chemother; 2001 Dec; 45(12):3538-43. PubMed ID: 11709336
[TBL] [Abstract][Full Text] [Related]
2. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans.
Baba M; Takashima K; Miyake H; Kanzaki N; Teshima K; Wang X; Shiraishi M; Iizawa Y
Antimicrob Agents Chemother; 2005 Nov; 49(11):4584-91. PubMed ID: 16251299
[TBL] [Abstract][Full Text] [Related]
3. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
[TBL] [Abstract][Full Text] [Related]
4. Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist.
Takashima K; Miyake H; Kanzaki N; Tagawa Y; Wang X; Sugihara Y; Iizawa Y; Baba M
Antimicrob Agents Chemother; 2005 Aug; 49(8):3474-82. PubMed ID: 16048963
[TBL] [Abstract][Full Text] [Related]
5. [Chemokine receptors and its importance in the replication cycle of human immunodeficiency virus: clinical and therapeutic implications].
Azevedo-Pereira JM; Santos-Costa Q
Acta Med Port; 2008; 21(5):497-504. PubMed ID: 19187693
[TBL] [Abstract][Full Text] [Related]
6. Consistent and significant inhibition of human immunodeficiency virus type 1 envelope-mediated membrane fusion by beta-chemokines (RANTES) in primary human macrophages.
Stantchev TS; Broder CC
J Infect Dis; 2000 Jul; 182(1):68-78. PubMed ID: 10882583
[TBL] [Abstract][Full Text] [Related]
7. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
Maeda K; Nakata H; Koh Y; Miyakawa T; Ogata H; Takaoka Y; Shibayama S; Sagawa K; Fukushima D; Moravek J; Koyanagi Y; Mitsuya H
J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: effects of viral diversity, target cell and receptor density.
Willey S; Peters PJ; Sullivan WM; Dorr P; Perros M; Clapham PR
Antiviral Res; 2005 Nov; 68(2):96-108. PubMed ID: 16157392
[TBL] [Abstract][Full Text] [Related]
9. The role of cholesterol and sphingolipids in chemokine receptor function and HIV-1 envelope glycoprotein-mediated fusion.
Ablan S; Rawat SS; Viard M; Wang JM; Puri A; Blumenthal R
Virol J; 2006 Dec; 3():104. PubMed ID: 17187670
[TBL] [Abstract][Full Text] [Related]
10. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5.
Dragic T; Trkola A; Thompson DA; Cormier EG; Kajumo FA; Maxwell E; Lin SW; Ying W; Smith SO; Sakmar TP; Moore JP
Proc Natl Acad Sci U S A; 2000 May; 97(10):5639-44. PubMed ID: 10779565
[TBL] [Abstract][Full Text] [Related]
11. The envelope gene is a cytopathic determinant of CCR5 tropic HIV-1.
Olivieri K; Scoggins RM; Bor YC; Matthews A; Mark D; Taylor JR; Chernauskas D; Hammarskjöld ML; Rekosh D; Camerini D
Virology; 2007 Feb; 358(1):23-38. PubMed ID: 16999983
[TBL] [Abstract][Full Text] [Related]
12. R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism.
Blanco J; Barretina J; Clotet B; Esté JA
J Leukoc Biol; 2004 Oct; 76(4):804-11. PubMed ID: 15258189
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation.
Alkhatib G; Locati M; Kennedy PE; Murphy PM; Berger EA
Virology; 1997 Aug; 234(2):340-8. PubMed ID: 9268166
[TBL] [Abstract][Full Text] [Related]
14. Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.
Seto M; Aikawa K; Miyamoto N; Aramaki Y; Kanzaki N; Takashima K; Kuze Y; Iizawa Y; Baba M; Shiraishi M
J Med Chem; 2006 Mar; 49(6):2037-48. PubMed ID: 16539392
[TBL] [Abstract][Full Text] [Related]
15. Prospects of HIV-1 entry inhibitors as novel therapeutics.
Pierson TC; Doms RW; Pöhlmann S
Rev Med Virol; 2004; 14(4):255-70. PubMed ID: 15248253
[TBL] [Abstract][Full Text] [Related]
16. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.
Trkola A; Ketas TJ; Nagashima KA; Zhao L; Cilliers T; Morris L; Moore JP; Maddon PJ; Olson WC
J Virol; 2001 Jan; 75(2):579-88. PubMed ID: 11134270
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of HIV-1 replication and infectivity by expression of a fusion protein, VPR-anti-integrase single-chain variable fragment (SFv): intravirion molecular therapies.
BouHamdan M; Kulkosky J; Duan LX; Pomerantz RJ
J Hum Virol; 2000; 3(1):6-15. PubMed ID: 10774802
[TBL] [Abstract][Full Text] [Related]
18. Establishment of a CCR5-expressing T-lymphoblastoid cell line highly susceptible to R5 HIV type 1.
Baba M; Miyake H; Okamoto M; Iizawa Y; Okonogi K
AIDS Res Hum Retroviruses; 2000 Jul; 16(10):935-41. PubMed ID: 10890354
[TBL] [Abstract][Full Text] [Related]
19. Relative concordance of human immunodeficiency virus oligomeric and monomeric envelope in CCR5 coreceptor usage.
Teeravechyan S; Suphaphiphat P; Essex M; Lee TH
Virology; 2008 Jan; 370(2):443-50. PubMed ID: 17936869
[TBL] [Abstract][Full Text] [Related]
20. The tripeptide glycyl-prolyl-glycine amide does not affect the early steps of the human immunodeficiency virus type 1 replication.
Su J; Naghavi MH; Jejcic A; Horal P; Furuta Y; Wu YP; Li SL; Hall WW; Goobar-Larsson L; Svennerholm B; Vahlne A
J Hum Virol; 2001; 4(1):8-15. PubMed ID: 11213934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
